Hidradenitis Suppurativa

HS Toolbox: Preparing Patients for Unexpected Flares

about 1 month ago

An HS toolbox with wound care, symptom relief, and personal care supplies can help patients stay prepared for unexpected flares.

Latest News

Biologic Therapies in AD and CSU: Progress and the Push for Precision Medicine 2 months ago

Probiotics in Hidradenitis Suppurativa: Biologic Rationale vs. Clinical Evidence 2 months ago

Financial Toxicity Linked to Worse Quality of Life in HS 5 months ago

Psychedelic Therapy-Informed Approaches to the Psychosocial Burden of HS 7 months ago

How to Build an HS Toolkit for Unpredictable Flares

New Immune-Mediated Therapies in AD, Alopecia Areata, and HS Presented at SDNP

Shorts

View All Shorts

0:19

A Surprising Hack for Managing HS Flares

a month ago

Chantel Hillestad, RN, MSN, DCNP, FNP-C,

0:15

HS is a Marathon, Not a Sprint

2 months ago

Martina Porter, MD

1:14

Don’t Be Rash: Fighting for Life-Changing HS Therapies in Pediatrics

5 months ago

Jillian Rork, MD(+1 more)

0:30

HS Breakthrough Excitement at AAD 2026

6 months ago

Steven Daveluy, MD

Continuing Medical Education

In-Person Event

DermNexus: The Inflammatory Disease and Innovations Congress for NP/PAs

November 20-21, 2026

Video

Clear Skin, Clear Mind: Integrating Mental Health into Psoriasis Care

John Koo, MD; T.J. Chao, MPAS, PA-C

Adaptive Learning

Medical Crossfire®: Navigating Chronic GVHD Prophylaxis and Treatment – Targeted Strategies to Elevate Patient Outcomes

Corey Cutler, MD, MPH, FRCP(C); Amin M. Alousi, MD; Mehdi Hamadani, MD; Anna Sureda, MD, PhD

Video

Publication Review: Defining On-Treatment Remission in Plaque Psoriasis

April W. Armstrong, MD, MPH; Tina Bhutani-Jacques MD

All News

Earlier Biologic Intervention Is Necessary in Moderate to Severe Hidradenitis Suppurativa

ByKaitlyn Bader, Assistant Managing Editor,Lakshi Aldredge, MSN, ANP-BC

March 17th 2026

Lakshi Aldredge, MSN, ANP-BC, DCNP, FAANP, reviewed clinical trial and long-term data supporting biologic therapies for HS, emphasizing individualized patient selection and timing of intervention.

FDA Approves Secukinumab for Pediatric HS, Creating First IL-17A Option for Adolescents

ByMaddi Hebebrand, MC, Associate Editor

March 13th 2026

Novartis secured the approval through a pharmacokinetic extrapolation strategy rather than a full pediatric RCT, leveraging adult HS trial data and existing pediatric PK modeling from other approved indications.

Deciphering Evolving Biologic Strategies for Hidradenitis Suppurativa

ByLakshi Aldredge, MSN, ANP-BC,Kaitlyn Bader, Assistant Managing Editor

January 6th 2026

At the Dermatology Times Horizons in Advanced Practice meeting in Tampa, Florida, conference chair Lakshi Aldredge, MSN, ANP-BC, DCNP, focused a discussion on efficacy data for adalimumab, secukinumab, and bimekizumab.